C-6WKEHeartseed Inc.
iPS cells, cardiac regenerative medicine, remuscularization
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-6WKE
C-6WKEC-6WKEiPS cells, cardiac regenerative medicine, remuscularization
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Heartseed Inc. iPS cells, cardiac regenerative medicine, remuscularization
Heartseed was founded in 2015 to transform treatment of severe heart failure by delivering cardiac regenerative medicine. Its lead pipeline is HS-001, an allogeneic iPS cell-derived regenerative cardiomyocyte therapy administered into the myocardium. The company is also researching autologous iPS cells, HLA-knockout iPS cells, and more broadly accessible administration methods.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Heartseed Inc. — Far from goals · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic